Please login to the form below

Intercept

This page shows the latest Intercept news and features for those working in and with pharma, biotech and healthcare.

Zydus Cadila scores first ever NASH approval, in India

Another potential treatment for NASH – from Intercept – is currently under review with the US Food and Drug Administration (FDA). ... additional information provided in response to FDA requests,” Intercept wrote in the filing at the time.

Latest news

FDA delays decision on Intercept's NASH drug by three months

Intercept confirmed the delay in a filing with the US Securities &Exchange Commission last week. ... additional information provided in response to FDA requests,” Intercept wrote in the filing.
Boehringer bolsters NASH pipeline with Enleofen link-up

Meanwhile, Intercept Pharma’s obeticholic acid (OCA) is under priority review at the FDA for the treatment of liver fibrosis due to NASH, and could become the first drug to treat
Provention Bio wins PRIME designation for type 1 diabetes prevention drug

1R inhibition intercepts the migration of inflammatory cells to the gut.
Type 1 diabetes prevention promise sends Provention Bio soaring

Provention Bio’s approach is to intercept the T1D process at an early stage of the autoimmune condition, which involves a set of autoantibodies being created in the body which eventually
Genfit presses the gas on NASH with combo trials

moment. It’s notable that Gilead now has a two disappointing late-stage trial readouts for its ASK1 inhibitor selonsertib in NASH, while front-runner Intercept is pitching its candidate Ocaliva

More from news
Approximately 10 fully matching, plus 17 partially matching documents found.

Latest Intelligence

Deal Watch June 2016

In Europe Cerus expects to apply for a CE Mark for the Intercept RBC System in the second half of 2016. ... collaboration, licence. 200. Cerus/ BARDA. Intercept, pathogen reduction technology for blood transfusions including Zika virus.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Simon Doyle joins STEM

Doyle - who joins the group from Intercept Pharmaceuticals where he was executive director of commercial operations and marketing - will be at the forefront of a number of key accounts to help
Glenn Sblendorio to retire as president of The Medicines Company

He currently serves as a director at Amicus Therapeutics, Intercept Pharmaceuticals and Ophthotech Corporation.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

Blog: 5 ingredients: Multichannel marketing, simplified

Develop your communication for each channel specifically. Intercept testing: show the ad to your mother, your child, a co-worker down the hall.
Market Insights Can Deliver a Better Patient Experience

Our survey, carried out using a mobile research intercept method, found that, unfortunately, memory aids can give patients the false reassurance that they are more compliant than they actually are.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Working together against COVID-19: Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19: Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?: Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....